Systems biology strategy through integrating metabolomics and network pharmacology to reveal the mechanisms of Xiaopi Hewei Capsule improves functional dyspepsia

Article

Author: Liu, Runhua ; Yu, Gengyuan ; Sun, Yikun ; Zhang, Tonghua ; Wang, Jiaqi ; Zhang, Chenning ; Sun, Yu ; Feng, Xin ; Li, Tianyi ; Wu, Hao ; Xu, Haoran ; Bi, Yuelin

Functional dyspepsia (FD) is one of the more common functional disorders, with a prevalence of 20-25 %. It seriously affects the quality life of patients. Xiaopi Hewei Capsule (XPHC) is a classic formula originated from the Chinese Miao minority. Clinical studies have demonstrated that XPHC can effectively alleviate the symptoms of FD, but the molecular mechanism has not been elucidated. The purpose of this work is to investigate the mechanism of XPHC on FD by integrating metabolomics and network pharmacology. The mice models of FD were established, and gastric emptying rate, small intestine propulsion rate, serum level of motilin and gastrin were evaluate to study the interventional effect of XPHC on FD. Next, a metabolomics strategy has been developed to screen differential metabolites and related metabolic pathways induced by XPHC. Then, prediction of active compounds, targets and pathways of XPHC in treating FD were carried out by commonly used network pharmacological method. Finally, two parts of the results were integrated to investigate therapeutic mechanism of XPHC on FD, which were preliminary validated based on molecular docking. Thus, twenty representative different metabolites and thirteen related pathways of XPHC in treating FD were identified. Most of these metabolites were restored using modulation after XPHC treatment. The results of the network pharmacology analysis showed ten crucial compounds and nine hub genes related to the treatment of FD with XPHC. The further integrated analysis focused on four key targets, such as albumin (ALB), epidermal growth factor receptor (EGFR), tumor necrosis factor (TNF) and roto-oncogene tyrosine-protein kinase Src (SRC), and three representative biomarkers such as citric acid, L-leucine and eicosapentaenoic acid. Furthermore, molecular docking results showed that ten bioactive compounds from XPHC have good binding interactions with the four key genes. The functional enrichment analysis indicated that the potential mechanism of XPHC in treating FD was mainly associated with energy metabolism, amino acid metabolism, lipid metabolism, inflammatory reactions and mucosal repair. Our work confirms that network pharmacology-integrated metabolomics strategyis a powerful means to reveal the therapeutic mechanisms of XPHC improves FD, which contribute its further scientific research.

01 May 2008·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Therapeutic effect of hewei xiaopi capsule for treatment of dyskinesis functional dyspepsia].

Article

Author: Xia, Li-Ying ; Ge, Wen-Jin ; Liu, Wei-Jia

OBJECTIVETo study the effect of Hewei Xiaopi Capsule (HXC) in treating patients with dyskinesis functional dyspepsia (FD).METHODSSixty-three patients with FD were randomly assigned to two groups, 33 in the treated group and 30 in the control group, who were treated respectively with HXC and domperidone for 4 weeks to observe the clinical effect and changes in electrogastrogram (EGG) before and after treatment.RESULTSSymptoms were alleviated in both groups after treatment, 3 patients in the treated group were cured, the efficacy was judged as markedly effective in 11, effective in 14 and ineffective in 5, while in the control group, 1 cured, 8 markedly effective, 14 effective and 7 ineffective, difference between the two groups showed no statistical significance. EGG showed that in the treated group, the normal slow-wave percentage was 41.93 +/- 18.22 before treatment and 50.86 +/- 16.03 after treatment, showing significant difference (P < 0.05).CONCLUSIONHXC is markedly effective in treating patients with FD.

01 Oct 2006·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical research on effects of yunpi zhixie granule in children with diarrhea].

Article

Author: Yan, Hui-min ; Yang, Yan

OBJECTIVETo investigate the clinical effect of Yunpi Zhixie Granule (YZG) on children's diarrhea.METHODSThree hundred diarrhea cases were randomly divided into two groups equally, the treated group treated by YZG orally and the control group by smacta, both for 7 days. The clinical efficacy was observed, routine scatologic analysis, scatologic cultivation, rotavirus antigen and urinary D-xylose content were detected.RESULTSClinical results showed the effective rate in treating the chronic or Pi-deficiency diarrhea as well as the negative conversion rate and improvement rate of routine scatologic analysis were all higher in the treated group than those in the control group (P < 0.05); while no significant difference was found in negative conversion rate of scatologic cultivation and rotavirus antigen and urinary D-xylose content after treatment, compared with those before treatment (P > 0.05).CONCLUSIONYZG was effective in treating children' s diarrhea, especially on chronic diarrhea and diarrhea of Pi-deficiency type.

100 Deals associated with Hewei Zhixie Capsule

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diarrhea	CN	Zhejiang Yongning Pharmaceutical Co. Ltd.	11 Jul 2018
Gastroenteritis	CN	Zhejiang Yongning Pharmaceutical Co. Ltd.	11 Jul 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Hewei Zhixie Capsule

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation